Cargando…
Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy, with increasing incidence over the past several decades. The majority of patients with HCC present with advanced unresectable disease, making treatment options with curative intent limited and survival outl...
Autores principales: | Machairas, Nikolaos, Tsilimigras, Diamantis I., Pawlik, Timothy M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025403/ https://www.ncbi.nlm.nih.gov/pubmed/35454923 http://dx.doi.org/10.3390/cancers14082018 |
Ejemplares similares
-
Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Ruff, Samantha M., et al.
Publicado: (2023) -
Meta-Analysis of Repeat Hepatectomy versus Radiofrequency Ablation for Recurrence of Hepatocellular Carcinoma
por: Machairas, Nikolaos, et al.
Publicado: (2022) -
Recurrent Hepatocellular Carcinoma: Patterns, Detection, Staging and Treatment
por: Papaconstantinou, Dimitrios, et al.
Publicado: (2022) -
Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020) -
The Immunology of Hepatocellular Carcinoma
por: Lawal, Gbemisola, et al.
Publicado: (2021)